Acrivon Therapeutics

Public

Watertown, MassachusettsHealthcarehttps://www.acrivon.com

Acrivon Therapeutics is now publicly traded

The data on this page reflects Acrivon Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Nov 14, 2022

Last Round

PIPE

Apr 9, 2024

Total Funding Raised

$344.9M

Company Overview

Acrivon Therapeutics operates in Healthcare and is based in Watertown, Massachusetts. Its recorded funding history includes a Series B round in November 2021.

Acrivon Therapeutics (NAS: ACRV) is a biopharmaceutical company focused on developing targeted oncology therapies matched to patients based on a proteomics-based responder identification platform.

Sector

Healthcare

AI Layer

Application

Acrivon Therapeutics Comparables

Compare Acrivon Therapeutics with similar companies based on industry and business-model similarity.

Acrivon Therapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap
FoRx Therapeutics	67%	Demo
Sentinel Oncology	56%	Demo
Arum Therapeutics	54%	Demo

Book a demo to see all comparables

For institutional investors. Book with your work email.

Acrivon Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
PIPE	Apr 9, 2024	Demo	Demo	Demo	Demo
IPO	Nov 14, 2022	Demo	Demo	Demo	Demo
Series B	Nov 11, 2021	Demo	Demo	Demo	Demo
Series A	Feb 1, 2021	Demo	Demo	Demo	Demo

Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Acrivon Therapeutics Investors

Notable investors and investment history

Acrivon Therapeutics investors
Investor	Rounds
Jefferies	IPO
Chione Ltd	Series A, Series B
RA Capital Advisors	Series B
RA Capital Management	PIPE, Series B
Perceptive Advisors	PIPE, Series B
OrbiMed	Series B
Paradigm BioCapital	PIPE